Skip to content

Four-year analysis of tenofovir finds “favourable safety profile”

A short course of potent HIV therapy during primary infection may slow longer-term disease progression

Offer second HIV test late in pregnancy to women with high HIV risk

WHO issues clarification on pharmacovigilance funding

Oral solution of bevirimat provides encouraging results, maturation inhibitor moves ahead

Global MDR and XDR TB control needs extra $2.15 billion by end of 2008, says WHO

Maraviroc approval delayed in the US

TB treatment and HBV: risk factors for liver toxicity in South Africans on antiretroviral therapy

Hospital admissions involving people with HIV fall by 40% between 2000 and 2004 in US